Adipotide is marketed as a fat-loss peptide. Its mechanism is genuinely
distinctive — and its safety record is the reason this monograph is cautious.
Chemical identity & structure.
Adipotide (also referred to as FTPP, a fat-targeted proapoptotic peptide) is a
synthetic peptide built as a two-part molecule: a targeting sequence joined to a
proapoptotic sequence. The targeting part is designed to home to the blood
vessels that supply white fat tissue.
Mechanism of action.
Adipotide's design is unusual. The targeting sequence binds a marker
(associated with prohibitin) on the blood vessels feeding white adipose tissue;
the attached proapoptotic sequence then triggers programmed cell death in those
vessels. Cutting the blood supply to fat tissue causes that fat to be resorbed.
It is, in effect, an anti-angiogenic approach to fat reduction — a very
different mechanism from appetite suppression or metabolic modulation.
Key research findings.
Preclinical research — including work in rodents and non-human primates —
reported weight and fat reduction. The same preclinical research also reported a
serious safety signal: effects on the kidney, where similar vasculature is
present. The kidney finding is the central caution in adipotide's record.
The research / citation base.
Adipotide's evidence base is preclinical. It is not approved for any
use, and the preclinical kidney-toxicity signal is a major reason it has not
advanced as a mainstream therapeutic. There is no body of human safety data.
Marketing adipotide as a fat-loss aid omits the central safety problem.
Human clinical trial data.
No human clinical trial has established administration parameters for adipotide; VialTalk does
not provide community-sourced dosing.
Quality & sourcing notes.
A batch-specific COA with mass-spectrometry identity and HPLC purity is the
minimum bar. As with other compounds here, the harder issue is the absence of
human safety data — no COA addresses the preclinical kidney signal.
*Research-use note: Educational summary of published research. Adipotide is a
non-approved compound with a preclinical kidney-toxicity signal; this is
research context only and not medical advice.*
